Effects of the CYP2C9*13 allele on the pharmacokinetics of losartan in healthy male subjects

Xenobiotica

Volumn 39, Issue 10, 2009, Pages 788-793

  Li, Z ^a   Wang, G ^a   Wang, L S ^a   Zhang, W ^a   Tan, Z R ^a   Fan, L ^a   Chen, B L ^a   Li, Q ^a   Liu, J ^a   Tu, J H ^a   Hu, D L ^a   Liu, Z Q ^a   Zhou, H H ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

CYP2C9; E3174; Lorartan; Pharmacokinetics; Polymorphism

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; CYTOCHROME P450 2C9; LOSARTAN; ANTIHYPERTENSIVE AGENT; CYP2C9 PROTEIN, HUMAN; IMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE; UNSPECIFIC MONOOXYGENASE;

ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; GENE FREQUENCY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; TANDEM MASS SPECTROMETRY; ASIAN; GENETICS; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ALLELES; ANTIHYPERTENSIVE AGENTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; HUMANS; IMIDAZOLES; LOSARTAN; MALE; TETRAZOLES; YOUNG ADULT;

EID: 70350658226     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250903134435     Document Type: Article

References (24)

1. Bae JW, Kim HK, Kim JH, Yang SI, Kim MJ, Jang CG, Park YS, Lee SY. (2005). Allele and genotype frequencies of CYP2C9 in a Korean population. Br J Clin Pharmacol 60(4):418-422
2. Gaedigk A, Casley WL, Tyndale RF, Sellers EM, Jurima Romet M, Leeder JS. (2001). Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. Can J Physiol Pharmacol 79:841-847
3. Goldberg MR, Lo MW, Bradstreet TE, Ritter MA, Höglund P. (1995). Effects of cimetidine on pharmacokinetics and pharmacodynamics of Iosartan, an ATl-selective non-peptide angiotensin II receptor antagonist. Eur J Clin Pharmacol 49(1-2):115-119
4. Guo Y, Wang Y, Si D, Fawcett PJ, Zhong D, Zhou H. (2004). Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13. Xenobiotica 35(9):853-861
5. Guo Y, Zhang Y, Wang Y, Chen X, Si D, Zhong D, Fawcett JP, Zhou H. (2005). Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans. Drug Metab Dispos 33(6):749-753
6. Han Y, Guo D, Chen Y, Chen Y, Tan ZR, Zhou HH. (2009). Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers. Eur J Clin Pharmacol 65(6):585-591
7. Kaukonen KM, Olkkola KT, Neuvonen PJ. (1998). Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. Eur J Clin Pharmacol 53(6):445-449
8. Kobayashi M, Takagi M, Fukumoto K, Kato R, Tanaka K, Ueno K. (2008). The effect of bucolome, a CYP2C9 inhibitor, on the pharmacokinetics of losartan. Drug Metab Pharmacokinet 23(2):115-119
9. Lo MW, Goldberg MR, McCrea JB, Lu H, Furtek CI, Bjornsson TD. (1995). Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 58(6):641-649
10. McCrea JB, Cribb A, Rushmore T, Osborne B, Gillen L, Lo MW, Waldman S, Bjornsson T, Spielberg S, Goldberg MR. (1999). Phenotypic and genotypic investigation of healthy volunteer deficient in conversion of losartan to its active metabolite E3174. Clin Pharmacol Ther 65(3):348-352
11. Ohtawa M, Takayama F, Saitoh K, Yoshinaga T, Nakashima M. (1993). Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist in humans. Br J Clin Pharmacol 35(3):290-297
12. Polinko M, Riffel K, Song H, Lo MW. (2003). Simultaneous determination of losartan and EXP3174 in human plasma and urine utilizing liquid chromatography/tandem mass spectrometry. J Pharm Biomed Anal 33(1):73-84.
13. Rettie AE, Jones JP. (2005). Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. Annu Rev Pharmacol Toxicol 45:477-494
14. Si D, Guo Y, Zhang Y, Yang L, Zhou H, Zhong D. (2004). Identification of a novel variant CYP2C9 allele in Chinese. Pharmacogenetics 14(7):465-469
15. Soldner A, Benet LZ, Mutschler E, Christians U. (2000). Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and Caco-2 cell monolayers. Br J Pharmacol 129(6):1235-1243
16. Stearns RA, Chakravarty PK, Chen R, Chiu SH. (1995). Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P450 2C and 3A subfamily members. Drug Metab Dispos 23(2):207-215
17. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA. (1996). The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6(4):341-349
18. Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye JA, Smith RD. (1993). Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 45(2):205-251
19. Wennerholm A, Nordmark A, Pihlsgard M, Mahindi M, Bertilsson L, Gustafsson LL. (2006). Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo. Eur J Clin Pharmacol 62(7):539-546
20. Williams PA, Cosme J, Ward A, Angove HC, Matak Vinkovic D, Jhoti H. (2003). Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 424(6947):464-468
21. Williamson KM, Patterson JH, McQueen RH, Adams KF, Pieper JA. (1998). Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 63(3):316-323
22. Yasar U, Babaoglu MO, Bozkurt A. (2008). Disposition of a CYP2C9 phenotyping agent, losartan, is not influenced by the common 3435C>T variation of the drug transporter gene ABCB1 (MDR1). Basic Clin Pharmacol Toxicol 103(2):176-179
23. Yasar U, Forslund-Bergengren C, Tybring G, Dorado PL, Lerena A, Sjöqvist F, Eliasson E, Dahl ML. (2002). Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin Pharmacol Ther 71(1):89-98.
24. Zhao F, Loke C, Rankin SC, Guo JY, Lee HS, Wu TS, Tan T, Liu TC, Lu WL, Lim YT, Zhang Q, Goh BC, Lee SC. (2004). Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin Pharmacol Ther 76(3):210-219